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Abstract
A two-step diagnostic algorithm is recommended to detect
Clostridium difﬁcile infections; however, samples are regularly found
that are glutamate dehydrogenase (GDH) positive but stool toxin
negative. In the present single-centre prospective study we
focused on these ‘difﬁcult-to-interpret’ samples and characterized
them by anaerobic culture, toxigenic culture, slpA sequence typing
and multiplex PCR (GenoType CDiff). The majority of stool toxin
A and B-negative samples have been caused by toxigenic strains
including ribotype 027. The multiplex PCR was faster and more
sensitive compared with culture and allowed preliminary identi-
ﬁcation of hypervirulent strains in stool samples on the same day.
Keywords: Clostridium difﬁcile, GDH, slpA sequence typing,
toxigenic culture, Toxin
Original Submission: 10 October 2013; Revised Submission:
15 December 2013; Accepted: 16 December 2013
Editor: F. Allerberger
Article published online: 23 January 2014
Clin Microbiol Infect 2014; 20: O590–O592
10.1111/1469-0691.12558
Corresponding author: L. von M€uller, MD, Institute of Medical
Microbiology and Hygiene, University Hospital of Saarland,
Kirrbergerstr., Building 43, D-66421 Homburg, Saar, Germany
E-mail: lutz.mueller@uks.eu
Clostridium difﬁcile is the most important pathogen causing
antibiotic-associated colitis. Most cases occur in the nosoco-
mial setting [1]. Fast and sensitive diagnostic assays are
essential for optimized disease management, including early
treatment and hygiene precautions [2,3]. In the current
ESCMID guidelines a two-step algorithm using glutamate
dehydrogenase (GDH) and toxin A and B antigen testing is
recommended [2,4]. In routine diagnostic combined toxin A
and B testing is regularly performed (toxin A/B) for
C. difﬁcile-negative (GDH and toxin A/B negative) and stool
toxin-positive infections (GDH and toxin A/B positive); this
strategy provides a diagnosis within one hour [5]. However,
GDH-positive but stool toxin-negative samples are also
regularly found [6]. This could be associated with non-
toxigenic strains but also with toxigenic strains in the case of
low or absent toxin production or false-negative toxin
testing [7,8].
The present single-centre prospective study of a tertiary
care 1200-bed university hospital (University of Saarland
Medical Centre) focussed speciﬁcally on hospitalized patients
with positive GDH but negative stool toxins (C. Diff Quik
Check Complete, Alere, K€oln, Germany). A total of 150 stools
were included in the study and investigated in parallel by
anaerobic culture (GENbox anaer and CLO-agar, bioMerieux,
N€urtingen, Germany) [9,10], toxin A/B testing of isolates (C.
Diff Quik Check Complete) (toxigenic culture) and a com-
mercial multiplex PCR (GenoType CDiff, Hain Lifescience,
Nehren, Germany). All C. difﬁcile isolates were conﬁrmed by
Maldi-TOF (Biotyper, Bruker Daltronics, Bremen, Germany).
Genotyping was performed using surface-layer protein A
sequence typing (slpAST) as described previously [10,11] and
slpA sequence types associated with ribotype groups were
indicated (Fig. 1). DNA of stool samples was isolated by
automated systems (GenoXtract, Hain Lifescience, or Max-
well, Promega, Mannheim, Germany). GenoType CDiff multi-
plex PCR was designed for the simultaneous detection of tpi
(triose phosphate isomerise), tcdA (toxin A), tcdB (toxin B),
cdtA and cdtB (binary toxin, CDT), and additionally character-
istic tcdC (potential regulator gene) and gyrA (gyrase A)
mutations. Using multiplex PCR the presence of C. difﬁcile (tpi),
the discrimination between toxigenic vs. non-toxigenic strains
and also preliminary typing of distinct ribotypes (027, 078) is
available in 3–4 h. All specimens with either positive C. difﬁcile
culture or positive tpi-PCR were classiﬁed as C. difﬁcile positive
(Table 1) while the identiﬁcation of toxigenic strains required
either the detection of toxin genes in stools or the presence of
toxin A/B in isolates (toxigenic culture).
Based on multiplex stool PCR and anaerobic culture a total
of 145 (96.7%) samples were classiﬁed as C. difﬁcile positive
and ﬁve (3.3%) as C. difﬁcile negative. Only 22.0% of toxin A/
B-negative samples were associated with non-toxigenic strains
while the majority of cases were caused by strains identiﬁed as
toxigenic (74.7%).
By anaerobic culture, C. difﬁcile isolates were obtained in
111 of 150 samples (74%), of which 82 were toxigenic (73.9%).
Although generally accepted as a standard reference method,
34 of 145 samples classiﬁed as C. difﬁcile positive were not
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detected by anaerobic culture (23.4%). Subsequent toxigenic
culture revealed few discrepant results as compared with the
multiplex PCR. Two tcdA and tcdB negative non-toxigenic
isolates (6.9%) were tested toxin A/B positive whereas 12
toxigenic isolates (14.6%) were toxin A/B negative.
When stools were tested by GenoType Cdiff multiplex
PCR, 135 of 150 specimens (90.0%) were C. difﬁcile (tpi)
positive and 107 of them were toxigenic; 96 (89.7%) were tcdA
and tcdB positive and 11 (10.3%) were also positive for binary
toxin gens (cdtA and cdtB). However, 10 samples remained
PCR negative despite identiﬁcation of toxigenic (n = 5) and
non-toxigenic (n = 5) C. difﬁcile isolates (6.9%).
Importantly, also hypervirulent strains (027 and 078) were
identiﬁed in toxin A/B-negative samples (slpAST) [10–12]
(Fig. 1). While slpAST, as other typing methods, can discrim-
inate epidemic outbreak strains as, for example, 027, recent
whole genome sequencing data revealed that slpA genes can be
associated with different ribotypes or pylogenetic groups
(MLST) [13]. The presence of different s-layer cassettes in
isolates of the same ribotype was conﬁrmed in the present
cohort for 014 strains detected within two distinct slpAST
groups (010/014 and 014/066). Distribution of the same s-layer
cassette in different ribotypes was also responsible for
identiﬁcation of toxigenic (014) and non-toxigenic strains
(010) in the same slpAST group (010/014).
Genotype Cdiff multiplex PCR generates complex genetic
C. difﬁcile proﬁles within a few hours to discriminate non-toxi-
genic, toxigenic and hypervirulent toxgenic strains [14,15].
Ribotype 027 (n = 5) and 078 strains (n = 3) were character-
ized by characteristic tcdC mutations, which were always
detected in the corresponding isolates but surprisingly not
always directly in stool samples (n = 2). These discrepancies
could be explained, for example, by co-infections of hypervir-
ulent with wild type strains.
The present exploratory study intentionally focused on
‘difﬁcult-to-interpret’ GDH-positive samples with negative
stool toxins and highlights the need for independent conﬁr-
matory testing. The diagnostic value of the various assays was
estimated as follows: GDH is recommended in current
guidelines as an initial sensitive screening test [16,17] and
accordingly only ﬁve samples (3.3%, presumably false-positive)
were not conﬁrmed to be C. difﬁcile positive by independent
culture or molecular testing.
Focusing on the stool toxin-negative cohort we demon-
strated that the majority of toxigenic strains (77%) were not
detected by the initial toxin A/B stool testing. Therefore, toxin
A/B testing alone is no longer acceptable as a screening test for
CDI, which is already mentioned in the current guidelines [8].
Only anaerobic culture allows detailed geno- and phenotypic
characterization of isolates; however, for a routine conﬁrma-
tory assay there are limitations with respect to turn-around
time (3–5 days) and sensitivity as compared with multiplex
PCR. Multiplex PCR proved to be a fast and sensitive
conﬁrmatory assay discriminating characteristic genetic pro-
ﬁles [3,18]; however, clinicians have to be notiﬁed that
molecular-based detection of toxigenic strains in the absence
TABLE 1. Comparison of anaerobic and toxigenic culture with multiplex PCR (GenoType Cdiff) of GDH-positive and toxin A/
B-negative stool samples. Each sample was classiﬁed as C. difﬁcile negative or positive (non-toxigenic vs. toxigenic) by culture- and
molecular-based conﬁrmatory testing. Fields with discrepant results are indicated by asterisks (*)
Classiﬁcation
Samples,
n (%) GDH Toxin A/B
Anaerobic
culture
Toxigenic
culture
C. difﬁcile
PCR (tpi)
Toxin PCR
(tcdA and tcdB)
C. difﬁcile negative 5 (3.3) +*   na  
C. difﬁcile positive
(non-toxigenic)
22 (14.7) +  +  + 
4 (2.7) +  * na + 
2 (1.3) +  + +* + 
5 (3.3) +  +  * *
C. difﬁcile positive
(toxigenic)
65 (43.3) + * + + + +
30 (20.0) + * * na + +
12 (8.0) + * + * + +
5 (3.3) + * + + * *
na, no isolates available.
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FIG. 1. SlpA sequence types of isolates sub-classiﬁed into toxigenic
vs. non-toxigenic strains. Of 111 isolates, 82 toxigenic strains were
identiﬁed in toxin A/B-negative stools, including hypervirulent
strains.
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of free stool toxins is not always only associated with CDI but
also with colonization [19,20].
In summary, in our hospital setting, these ‘difﬁcult-to-inter-
pret’ results of GDH-positive but toxin A/B-negative samples
(C. diff Quik Check complete) were predominantly caused by
toxigenic strains. Therefore, independent culture- or molec-
ular-based conﬁrmatory assays are required for reliable
detection of toxigenic strains in GDH-positive but stool toxin
negative samples.
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